At the MM&M Transforming Healthcare conference, Iyengar told attendees how to take into account a consumer's behavior and emotion when marketing medical products.
The Siri for Seniors took the top prize at the second MM&M Shark Tank for its annual healthcare conference.
Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.
U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers
Did your agency report record growth in 2015? Tell us why when you fill out the A-to-Z questionnaire for MM&M's upcoming agency issue. The deadline is Friday.
The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign
IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service
Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.
The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.
Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug
The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.
The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.
The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.
Publicis Healthcare Communications Group has hired Kipp Jarecke-Cheng as global chief communications officer.
Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula
The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.
Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.
FDA panel says Duchenne drug is not effective; Bill Ackman to appear before Senate committee investigating pricing issues; Daiichi Sankyo to open new headquarters
Verywell.com presents physician-reviewed health and wellness content that aims to be "gentler" than other health websites.
The drugmaker disclosed in its first-quarter earnings report that it is being investigated over ties to nonprofit foundations.
After six years as president of Trio, Renée Wills has joined newly formed agency Kinch.
Valeant names new CEO; Novartis weighs sales of stake in Roche; FDA ad panel to recommend DMD drug
Too often left undiscussed is that a powerful business case can be made for more frequent and focused mentorship.
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Biogen CEO George Scangos told investors that the company's DTC campaign for Tecfidera was designed to address low awareness for the drug.
Allergan plans sales blitz for Kybella; Novartis U.S. lead steps down; analysts say PCSK9 sales are disappointing so far
IBM Watson Health has publicly announced deals with 18 different companies and patient organizations over the past few years.
The billboards themselves operate on simple principles: fool mosquitoes into thinking they've found a human, and then trap them until they die of dehydration.
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
Industry is partnering with Watson to try and solve some of healthcare's most pressing questions.
The company said growth in its immunology portfolio offset declining Olysio sales.
Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class
The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.
Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.
IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.
He plans to expand the company's consumer health marketing.
Valeant mulls over fire sale; research shows that Opdivo helps advanced melanoma patients survive longer; AstraZeneca considers Medivation
The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.
Already, there's cognitive cooking for your kitchen and cognitive coaching for your daily run. What's Watson's vision for medicine?
Healthcare and tech executives say it's possible for pharma to engage, use humor, and have fun on social media.
The editorial staff of MM&M recently visited IBM Watson's offices in New York. What ensued was the creation of Watson Week.
Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs
The questionnaire gives agencies the opportunity to contribute information to MM&M's definitive Agency A-to-Z directory, which will be published in the July issue.
Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license
With a lead role in IBM Watson's bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise's most important individuals.
2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.
Sanofi is reportedly interested in buying Medivation; Sean Parker funds $250 million cancer research institute; FDA will review Merck's allergy biologic
Industry criticism can create opportunities for drugmakers and other healthcare organizations to create a stronger narrative.
The FDA advisory committee voted 12-1 against approving the therapy, citing safety issues and requesting more data.
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
Analysts have estimated the drug could reach $2 billion in sales in the next four years.
"I continue to look for ways to stretch myself or ways I can get involved or influence the business," said the new CCO of Cello Health.
Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review
Here are the brands and companies that advertised the most on professional ads in 2015.
Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.
Learn about Merck's new innovation team as well as read profiles of 9 other teams at companies such as Google and Johnson & Johnson.
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's
LLNS CEO Sharon Callahan has been named CEO of TBWA/WorldHealth, which is based in New York.
Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.
It operates a number of ad agencies, like GSW and Palio, as well as a group of PR firms that includes Chandler Chicco Agency.
The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire
As tech behemoths like Google are attempting to poach the best and brightest, executives from pharma companies and agencies share new retention tactics.
CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.
The drugmaker instead suggested using an economic model it developed.
Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza
The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.
Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data
The drugmaker marketed a co-pay assistance voucher that failed to provide any risk information about its drug Ulesfia.
Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.
Great DTC pharma advertising during the last year or so has been "sparse," says SSCG Media Group president Debbie Renner. Still, here are her top 10 picks for 2015.
DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.
GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
Tip: Don't charge your intern with assembling your entry. Read more from our checklists of do's and don'ts, and don't forget that entries are due April 11.
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
The FTC asks for more info about Pfizer-Allergan deal; the FDA loosens guidelines for abortion-inducing drug; startup to deliver Truvada through an app
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center
The Boston-based agency was acquired by Precision Medicine Group in May.
Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.
The healthcare-focused agency network is committed to spending $50,000 over three years to the Future Leaders in Healthcare Fellowship Program.
WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.
The Catholic health system worked with FleishmanHillard and GSD&M to create the integrated campaign touting its partnership with the Department of Veterans Affairs.
Lawmakers call out high price of Xtandi; Novo Nordisk breaks ground in North Carolina; Sanofi poaches top research scientist from AstraZeneca
Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.
Experts say DTC spending is a waste; Alder BioPharma's migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences
The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.
Symptom-driven care is falling out of favor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.
Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.
GlaxoSmithKline's Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim's Spiriva Handihaler ($3.4 billion) and AstraZeneca's Symbicort ($2.6 billion).
Giant appointed Ben Mallory, who has held creative leadership roles at AstraZeneca, as its new executive creative director.
Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.
Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren't prescribed blood thinners; the FDA issues generic opioid guidance
Valeant hiked price of assisted-suicide drug; Bristol-Myers Squibb acquires autoimmune drugmaker; the FDA approves Teva's asthma drug
Facebook has found that 43% of people who watch the first three seconds of a video will stay for 10 seconds. To create engagement, agencies need to rethink the creative approach.
Anti-DTC measures are unlikely to be enacted even though the backlash itself is a function of political change.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
Click here to learn about the Agency Issue.